Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) EBT Margin (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed EBT Margin for 12 consecutive years, with 237.65% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin fell 25499.0% year-over-year to 237.65%, compared with a TTM value of 24.87% through Sep 2025, up 1298.0%, and an annual FY2024 reading of 23.24%, up 1996.0% over the prior year.
  • EBT Margin was 237.65% for Q3 2025 at CytomX Therapeutics, down from 0.48% in the prior quarter.
  • Across five years, EBT Margin topped out at 49.72% in Q4 2024 and bottomed at 927.7% in Q4 2022.
  • Average EBT Margin over 5 years is 146.09%, with a median of 25.81% recorded in 2024.
  • The sharpest move saw EBT Margin crashed -61488bps in 2022, then skyrocketed 93486bps in 2023.
  • Year by year, EBT Margin stood at 312.82% in 2021, then crashed by -197bps to 927.7% in 2022, then surged by 101bps to 7.16% in 2023, then surged by 594bps to 49.72% in 2024, then crashed by -578bps to 237.65% in 2025.
  • Business Quant data shows EBT Margin for CTMX at 237.65% in Q3 2025, 0.48% in Q2 2025, and 46.32% in Q1 2025.